$VTRS (Viatris Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 31.2%)

Graded daily on value B+, growth D-, profitability C, momentum B+, revisions B-. Sector-relative, identical for every user.

Most active credible voices on $VTRS

@marketrebels (Market Rebellion) — 8 mentions · 367.6K followers
@stockmktnewz (Evan) — 4 mentions · 1.2M followers
@ewhispers (Earnings Whispers) — 3 mentions · 570.9K followers

Recent headlines featuring $VTRS

2026-10-08: Viatris agrees to buy Pacira for $1.65 billion

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $VTRS are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$VTRS (Viatris Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 31.2%)

Graded daily on value B+, growth D-, profitability C, momentum B+, revisions B-. Sector-relative, identical for every user.

Most active credible voices on $VTRS

@marketrebels (Market Rebellion) — 8 mentions · 367.6K followers
@stockmktnewz (Evan) — 4 mentions · 1.2M followers
@ewhispers (Earnings Whispers) — 3 mentions · 570.9K followers

Recent headlines featuring $VTRS

2026-10-08: Viatris agrees to buy Pacira for $1.65 billion

Pro Analysis Available: Full unrolled post citations, institutional 13F filing matrix, and real-time sentiment alerts for $VTRS are available with SpikePanel Pro.

Stock Ratings · Today Headlines · SpikePanel

$VTRSViatris Inc. · Drug Manufacturers - Specialty & Generic · $20.3B

$17.44

pre+0.0%

Event thread

Key events, in time order

10 items

2026-10-088-K filing
8-K: Item 1.01, Item 8.01, Item 9.01
D1 -0.3%
2026-10-08Capital
Viatris to Acquire Pacira BioSciences for $1.65B
Deal adds non-opioid pain drugs EXPAREL and ZILRETTA, expanding innovative medicines portfolio
D1 -0.3%

8 earlier events

2026-08-06EarningsBull
Viatris Beats Q2 Estimates, Raises Outlook, Divests Tyrvaya
Q2 revenue $3.8B beat, raised guidance, divested Tyrvaya to Harrow
D1 -7.7% · +5d -1.5%
2 waves of this story
- 2026-08-06 Revenue and adjusted EPS beat estimates, Greater China sales up 21%, company raises 2026 outlook.
- 2026-08-06 Q2 revenue $3.8B beat, raised guidance, divested Tyrvaya to Harrow
2026-08-06Earnings
Earnings report
D1 -7.7% · +5d -1.5%
2026-08-068-K filing
8-K: Item 2.02, Item 8.01, Item 9.01
D1 -7.7% · +5d -1.5%
2026-08-04CapitalBull
Viatris Declares Quarterly Dividend of $0.12 per Share
Board declared on Aug 3, reflecting shareholder return commitment
D1 +0.4% · +5d -8.0%
2026-07-29ProductBull
Viatris Gains FDA Approval for Once-Weekly Contraceptive Patch Gwyn Lo
First once-weekly low-dose estrogen combo contraceptive patch approved, advancing women's health portfolio
D1 -0.2% · +5d -1.0%
2026-07-018-K filing
8-K: Item 1.01, Item 2.03, Item 9.01
D1 +1.9% · +5d +1.0%
2026-06-188-K filing
8-K: Item 1.01, Item 2.03, Item 9.01
D1 -2.3% · +5d +6.2%
2026-06-158-K filing
8-K: Item 8.01, Item 9.01
D1 -1.0% · +5d -3.5%

①

Bull vs bear

by direction · sourced

Bull signals0

None yet

Bear signals0

None yet

Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice

⑩

Discussion

be the first

Be civil · your views are your own

No comments yet.

Facts and opinions separated · All items sourced · Not investment advice

Event thread

Key events, in time order

10 items

2026-10-088-K filing
8-K: Item 1.01, Item 8.01, Item 9.01
D1 -0.3%
2026-10-08Capital
Viatris to Acquire Pacira BioSciences for $1.65B
Deal adds non-opioid pain drugs EXPAREL and ZILRETTA, expanding innovative medicines portfolio
D1 -0.3%
2026-08-06EarningsBull
Viatris Beats Q2 Estimates, Raises Outlook, Divests Tyrvaya
Q2 revenue $3.8B beat, raised guidance, divested Tyrvaya to Harrow
D1 -7.7% · +5d -1.5%
2 waves of this story
- 2026-08-06 Revenue and adjusted EPS beat estimates, Greater China sales up 21%, company raises 2026 outlook.
- 2026-08-06 Q2 revenue $3.8B beat, raised guidance, divested Tyrvaya to Harrow
2026-08-06Earnings
Earnings report
D1 -7.7% · +5d -1.5%
2026-08-068-K filing
8-K: Item 2.02, Item 8.01, Item 9.01
D1 -7.7% · +5d -1.5%

5 earlier events

2026-08-04CapitalBull
Viatris Declares Quarterly Dividend of $0.12 per Share
Board declared on Aug 3, reflecting shareholder return commitment
D1 +0.4% · +5d -8.0%
2026-07-29ProductBull
Viatris Gains FDA Approval for Once-Weekly Contraceptive Patch Gwyn Lo
First once-weekly low-dose estrogen combo contraceptive patch approved, advancing women's health portfolio
D1 -0.2% · +5d -1.0%
2026-07-018-K filing
8-K: Item 1.01, Item 2.03, Item 9.01
D1 +1.9% · +5d +1.0%
2026-06-188-K filing
8-K: Item 1.01, Item 2.03, Item 9.01
D1 -2.3% · +5d +6.2%
2026-06-158-K filing
8-K: Item 8.01, Item 9.01
D1 -1.0% · +5d -3.5%

$VTRS (Viatris Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 31.2%)

Most active credible voices on $VTRS

Recent headlines featuring $VTRS

$VTRS (Viatris Inc.) — investor discussion on X

Five-factor rating: Hold (sector percentile 31.2%)

Most active credible voices on $VTRS

Recent headlines featuring $VTRS

8-K: Item 1.01, Item 8.01, Item 9.01

Viatris to Acquire Pacira BioSciences for $1.65B

Viatris Beats Q2 Estimates, Raises Outlook, Divests Tyrvaya

Earnings report

8-K: Item 2.02, Item 8.01, Item 9.01

Viatris Declares Quarterly Dividend of $0.12 per Share

Viatris Gains FDA Approval for Once-Weekly Contraceptive Patch Gwyn Lo

8-K: Item 1.01, Item 2.03, Item 9.01

8-K: Item 1.01, Item 2.03, Item 9.01

8-K: Item 8.01, Item 9.01

Bull vs bear

Discussion

8-K: Item 1.01, Item 8.01, Item 9.01

Viatris to Acquire Pacira BioSciences for $1.65B

Viatris Beats Q2 Estimates, Raises Outlook, Divests Tyrvaya

Earnings report

8-K: Item 2.02, Item 8.01, Item 9.01

Viatris Declares Quarterly Dividend of $0.12 per Share

Viatris Gains FDA Approval for Once-Weekly Contraceptive Patch Gwyn Lo

8-K: Item 1.01, Item 2.03, Item 9.01

8-K: Item 1.01, Item 2.03, Item 9.01

8-K: Item 8.01, Item 9.01